Zapomeran
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | mRNA |
| Clinical data | |
| Trade names | Kostaive |
| Other names | ARCT-154, MRNA-2105 |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Zapomeran, sold under the brand name Kostaive is a self-amplifying mRNA-based COVID-19 vaccine.[1] It contains a self-amplifying mRNA that encodes the SARS-CoV-2 spike protein.[1] Self-amplifying means that the mRNA also carries instructions to make a protein called replicase.[1]
It was developed under the name ARCT-154, also known as VBC-COV19-154 in Vietnam, by Arcturus Therapeutics.[3][4] For its development, Arcturus collaborated with Vinbiocare, a Vietnamese company, for support with clinical trials and manufacturing.
Zapomeran was approved for medical use in Japan in November 2023,[5] and it is the first self-amplifying mRNA-based COVID-19 vaccine to be approved.[6][7] Zapomeran was authorized for medical use in the European Union in February 2025.[1][2][8]
- ^ a b c d e Cite error: The named reference
Kostaive EPARwas invoked but never defined (see the help page). - ^ a b Cite error: The named reference
Kostaive PIwas invoked but never defined (see the help page). - ^ Cite error: The named reference
yahoo0208was invoked but never defined (see the help page). - ^ Cite error: The named reference
Bloombergwas invoked but never defined (see the help page). - ^ Ra J (13 September 2024). "Japan approves updated Covid-19 vaccine to tackle JN.1 variant". Pharmaceutical Technology. Retrieved 16 December 2024.
- ^ https://www.meiji-seika-pharma.co.jp/pressrelease/2023/detail/pdf/231128_01.pdf
- ^ "Kostaive European Medicines Agency (EMA)". www.ema.europa.eu. European Medicines Agency. 26 February 2025. Retrieved 17 May 2025.